MOLN Molecular Partners

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcoming investor events in Switzerland during January 2023.

Conference Presentation Details:

JP Morgan 41st Annual Healthcare Conference

  • Wednesday, January 11, 2023, at 10:30 am ET (4:30 pm CET)

Baader Helvea Swiss Equities Conference

  • Thursday, January 12, 2023, at 10:00 am ET (4:00 pm CET)

Conference Participation Details:

The Octavian Seminar 2023

  • Friday, January 13, 2023

All webcasted presentations will be made available on the Molecular Partners .

About Molecular Partners AG 

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology, and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. ; Find us on Twitter - 

For further details, please contact:

Seth Lewis, Head of Investor Relations & Strategy

Concord, Massachusetts, U.S.



Tel:

Antonio Ligi, Head of Communications

Zurich-Schlieren, Switzerland



Tel: 1



EN
30/12/2022

Underlying

MOLNMolecular Partners

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Announces Participation in March Investor Conferenc...

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details o...

February 26, 2026 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Signs Development Agreement with Eckert & Ziegler f...

Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Announces Presentation of First Imaging and Dosimet...

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine exper...

February 2, 2026 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Highlights Clinical Development Progress and Antici...

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinomaPhase 1/2a trial of multi-specific T cell engager MP0533 on...

January 11, 2026 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Co...

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco, CA, USA. Chief Executive Officer Patrick Amstutz will pres...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch